Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Buclizine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | CNR1 | P21554 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | GHSR | Q92847 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.65 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.65 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.65 |
| ▸ | DRD1 | P21728 | 3/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.65 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.65 |
| ▸ | DRD3 | P35462 | 3/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Buclizine SCHEMBL22171621 | 1.00 | KCNH2 (1.00) | KCNH2LMNAADORA3CNR1HRH1 | |
| Buclizine SCHEMBL27855 | 1.00 | KCNH2 (1.00) | KCNH2LMNAADORA3CNR1HRH1 | |
| Buclizine SCHEMBL123751 | 0.99 | KCNH2 (0.98) | KCNH2LMNAADORA3CNR1HRH1 | |
| Buclizine SCHEMBL123753 | 0.99 | KCNH2 (0.98) | KCNH2LMNAADORA3CNR1HRH1 | |
| Buclizine SCHEMBL10769522 | 0.90 | CYP3A4 (0.84) | KCNH2LMNAADORA3CNR1HRH1 | |
| SCHEMBL12464946 | 0.89 | KCNH2 (0.80) | KCNH2LMNAADORA3CNR1HRH1 | |
| SCHEMBL3611802 | 0.87 | KCNH2 (0.78) | KCNH2LMNAADORA3CNR1HRH1 | |
| SCHEMBL588110 | 0.87 | KCNH2 (0.78) | KCNH2LMNAADORA3CNR1HRH1 | |
| SCHEMBL588111 | 0.87 | KCNH2 (0.78) | KCNH2LMNAADORA3CNR1HRH1 | |
| Hydrochloric Acid SCHEMBL588128 | 0.85 | LMNA (0.79) | KCNH2LMNAADORA3CNR1HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 523 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9757376-B2 | Pharmaceutical compositions | GM PHARMACEUTICALS, INC. (US) | 2017-09-12 | — | — | US | claimed |
| US-20160338972-A1 | SUBLINGUAL FILMS | SUNOVION PHARMACEUTICALS INC. | 2016-11-24 | — | — | US | claimed |
| US-20160151299-A1 | SUBLINGUAL FILMS | SUNOVION PHARMACEUTICALS INC. | 2016-06-02 | — | — | US | claimed |
| US-20140377329-A1 | SUBLINGUAL FILMS | SUNOVION PHARMACEUTICALS INC. | 2014-12-25 | — | — | US | claimed |
| CN-103648493-A | Subcutaneously infusible levodopa prodrug compositions and methods of infusion | SYNAGILE CORP | 2014-03-19 | — | — | CN | claimed |
| EP-2651357-A1 | SUBLINGUAL FILMS | Cynapsus Therapeutics Inc. (CA) | 2013-10-23 | — | — | EP | claimed |
| EP-2648716-A2 | SUBCUTANEOUSLY INFUSIBLE LEVODOPA PRODRUG COMPOSITIONS AND METHODS OF INFUSION | Synagile Corporation (US) | 2013-10-16 | — | — | EP | claimed |
| US-8431591-B2 | R(−)-2-methoxy-11-hydroxyaporphine and derivatives thereof | THE MCLEAN HOSPITAL CORPORATION (US) | 2013-04-30 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| EP-1341536-A2 | TREATMENT OF ANTI-DEPRESSION DRUG-INDUCED SEXUAL DYSFUNCTION WITH APOMORPHINE | TAP Pharmaceutical Products, Inc. (US) | 2003-09-10 | — | — | EP | claimed |
| US-6528521-B2 | May be utilized for patients taking anti-depressants such as tricyclic anti-depressants, monamine oxidase inhibitors or serotonin selective reuptake inhibitors. | TAP PHARMACEUTICAL PRODUCTS, INC. | 2003-03-04 | — | — | US | claimed |
| US-20020115683-A1 | Treatment of anti-depression drug-induced sexual dysfunction with apomorphine | RUFF DUSTIN D (US) | 2002-08-22 | — | — | US | claimed |
| US-20020086876-A1 | Treatment of anti-depression drug-induced sexual dysfunction with apomorphine | RUFF DUSTIN D (US) | 2002-07-04 | — | — | US | claimed |
| WO-2002039879-A2 | TREATMENT OF ANTI-DEPRESSION DRUG-INDUCED SEXUAL DYSFUNCTION WITH APOMORPHINE | TAP PHARMACEUTICAL PRODUCTS, INC. (US) | 2002-05-23 | — | — | WO | claimed |
| CN-1335772-A | Use of apomorphine in the manufacture of a medicament for the treatment of organic erectile dysfunction in males | ABBOTT LAB (US) | 2002-02-13 | — | — | CN | claimed |
| EP-1140094-A1 | USE OF APOMORPHINE IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF ORGANIC ERECTILE DYSFUNCTION IN MALES | ABBOTT LABORATORIES (US) | 2001-10-10 | — | — | EP | claimed |
| US-6291471-B1 | Use of apomorphine for the treatment of organic erectile dysfunction in males | ABB HOLDINGS, INC. | 2001-09-18 | — | — | US | claimed |
| WO-2000035457-A1 | USE OF APOMORPHINE IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF ORGANIC ERECTILE DYSFUNCTION IN MALES | ABBOTT LABORATORIES (US) | 2000-06-22 | — | — | WO | claimed |
| US-5053396-A | For treatment of symptoms associated with excessive alcohol intake, analgesic; nicotinamide or nicotinamide adenine dinucleotide | BLASS DAVID H (GB) | 1991-10-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086876-A1 | Treatment of anti-depression drug-induced sexual dysfunction with apomorphine | MAOA, SLC6A2, MAOB | HRH1 202/4885KCNH2 1918/4885LMNA 3290/4885 |
| US-20140377329-A1 | SUBLINGUAL FILMS | SNCA, COMT, HTR5A | HRH1 1049/4885KCNH2 2088/4885LMNA 2726/4885 |
| US-20160338972-A1 | SUBLINGUAL FILMS | SNCA, COMT, HTR5A | HRH1 1049/4885KCNH2 2088/4885LMNA 2726/4885 |
| US-20020115683-A1 | Treatment of anti-depression drug-induced sexual dysfunction with apomorphine | MAOA, SLC6A2, MAOB | HRH1 202/4885KCNH2 1918/4885LMNA 3290/4885 |
| US-20160151299-A1 | SUBLINGUAL FILMS | SNCA, COMT, HTR5A | HRH1 1049/4885KCNH2 2088/4885LMNA 2726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.